Porcine Respiratory Coronavirus
LEVELS: Highly unlikely; No human illness; Already in the herd; Laboratory-dependent; Minor; Negligible; Little; Available, or not needed
| Register id | porcine_respiratory_coronavirus |
| Type | virus |
| Scientific name | Porcine respiratory coronavirus |
| NCBI taxid | 11146 |
| Evidence | 3 document(s) |
| Assigned | 2026-09-06, against criteria version 093366e352a2 |
Overview
Porcine respiratory coronavirus is a naturally occurring mutant of transmissible gastroenteritis virus, first isolated in Belgium in 1984. A deletion of roughly 650 nucleotides in the spike gene changed what the virus binds to, and with it where it grows: PRCV multiplies in the lining of the respiratory tract rather than the gut, and is shed little or not at all in faeces. The infection it causes is usually silent, or a mild self-limiting respiratory illness that the pig's own immunity clears. It spread rapidly through Europe and the United States after it emerged and is now endemic even in countries free of TGEV. Its importance is almost entirely indirect and almost entirely beneficial: because it is closely related to TGEV, infection leaves pigs with cross-reacting antibody that partly protects them against the enteric parent virus, and this is the main reason transmissible gastroenteritis is far less damaging than it was. Several novel PRCV variants forming distinct genetic clusters have been found in US pigs since 2017, suggesting the virus is still evolving.
C1 Zoonotic potential
Likelihood of transmission from pigs to humans
Highly unlikely: Human infection with the agent has never been reported, or has been reported but is not attributed to pig or pork exposure
CONFIRMED by Eric. The assignment reached this level from the evidence, and he has reviewed and ratified it.
Confirmed by Eric. CONFIRMED. "c1l1, agree with assessment"
Basis. ch28 28.2.3, the public health section covering both TGEV and PRCV: "Pigs are the main species naturally susceptible to TGEV and PRCV. No infection of humans has been reported; however, novel canine-feline-swine spike recombinant alpha-CoVs (CCoV-HuPn-2018 and HuCCoV-Z19) with a CCoV-IIb backbone and closely related to TGEV have been identified recently in human pneumonia or febrile illness cases." SECOND SOURCE, puente_2026: "TGEV and PRCV possess a well-established capacity to infect and seroconvert companion animals (dogs and cats) under experimental and field settings, YET THEY POSE NO ZOONOTIC RISK." shic_prcv: "PRCV is not zoonotic and infects only swine."
How this level was decided
Level 1. No human infection with the agent itself has ever been reported. FLAGGED, because the chapter puts a genuine caveat in the same sentence and it should not be lost: recombinant alpha-coronaviruses closely related to TGEV, on a canine coronavirus backbone, have recently been recovered from people with pneumonia or febrile illness. Those are different viruses on a different backbone, and this cell scores this agent -- but the family demonstrably crosses into people, which is why the level is recorded as an examined negative on TGEV rather than as a statement about alpha-coronaviruses. Corroborated 2026-09-04 by a review that grades every porcine coronavirus for zoonotic risk and puts PRCV at none. Level 1 confirmed by direct statement.
C2 Zoonotic impact
Severity of human illness caused by the agent
No human illness: Agent does not cause illness in people
Basis. ch28 28.2.3, the public health section covering both TGEV and PRCV: "Pigs are the main species naturally susceptible to TGEV and PRCV. No infection of humans has been reported; however, novel canine-feline-swine spike recombinant alpha-CoVs (CCoV-HuPn-2018 and HuCCoV-Z19) with a CCoV-IIb backbone and closely related to TGEV have been identified recently in human pneumonia or febrile illness cases." shic_prcv: "PRCV is not zoonotic and infects only swine."
How this level was decided
Level 1. No human infection with PRCV has been reported, and PRCV is a deletion mutant of TGEV about which the chapter makes the same statement. Level 1 confirmed.
C3 Herd introduction risk
Effort required to keep the agent out of the herd
Already in the herd: Present in most herds, or carried by pigs themselves, so there is no introduction event to prevent
CONFIRMED by Eric. The assignment reached this level from the evidence, and he has reviewed and ratified it.
Confirmed by Eric. CONFIRMED. "c3l1, agree with assessment. Do not have a recent surveillance of US farms but clinically is not apparent and assumed to be present on most farms"
Basis. ch28 28.2.4.2: PRCV "spread rapidly and extensively in pigs in Europe and became endemic even in TGEV-free countries." "A limited serological survey in 1995 in the United States suggested that many asymptomatic herds in Iowa were seropositive for PRCV." "PRCV persists in closed breeding farms by regularly infecting newly-weaned pigs, even in the presence of maternal antibodies." "PRCV circulates in the herd, infecting pigs before the age of 10-15 weeks after passively acquired maternal antibodies have declined." SECOND SOURCE, puente_2026: "Rapid airborne dissemination in the European pig population, and later in North America, induced effective cross-immunity to TGEV, markedly reducing TGE incidence." PRCV "replicates almost exclusively in the respiratory tract and rarely causes clinical signs, but it has major epidemiological importance by inducing cross-protection against TGEV, though not against other CoVs." shic_prcv: "PRCV is spread via aerosol and direct contact between pigs." "In highly swine-dense areas PRCV can spread several kilometers by aerosol." "PRCV can be eliminated from herds by using an all-in all-out method where piglets are weaned early and transported to facilities that are PRCV-free." "Establishment of PRCV-negative herds is possible. Maintenance of PRCV-negative status can be achieved using strict biosecurity measures."
How this level was decided
Level 1. PRCV is endemic in the pig population, it persists inside CLOSED breeding farms by reinfecting each weaned group as maternal antibody wanes, and it does so in the presence of that antibody. There is no introduction event to prevent because the virus is already there and renews itself from within. FLAGGED as a level 1 or 4 judgment, because the chapter also records an airborne route of unusual reach -- "the virus can travel several kilometers" in areas of high swine density, and PRCV "can disappear in summer and reappear in the nursery and fattening units in winter", which is reintroduction rather than persistence. For a genuinely naive unit that airborne route is unblockable by any housing system, which is level 4. Scored level 1 because most US herds are not naive. Corroborated 2026-09-04: puente_2026 describes the same picture of a virus that spread through whole national pig populations by air and stayed. Eric confirmed level 1 on 2026-09-02 -- "do not have a recent surveillance of US farms but clinically is not apparent and assumed to be present on most farms" -- and the airborne-reach flag above is unchanged by the new source. LEVEL 1 HELD, AND FLAGGED, because the new source argues against it more strongly than anything previously in the folder. Level 1 says there is no introduction event to prevent -- but the factsheet states that PRCV-negative herds can be established and maintained with strict biosecurity, and that elimination by early weaning works. That reads like level 3 or 4, not level 1, and the several-kilometre aerosol spread in dense areas is a level 4 argument specifically. I have not moved it because the cell was assessed as endemic-in-the-US and the factsheet agrees PRCV is established here with unknown prevalence. Whether the entry means the endemic reality or the achievable-negative-status possibility is the same question as teschovirus_a, and Eric should settle it the same way.
C4 Detection difficulty
Difficulty of recognizing and confirming infection
Laboratory-dependent: The presentation does not point to this disease specifically, but local or regional laboratories can confirm it with a validated assay once it is suspected
Basis. ch28 28.2.6.3: "Experimentally, PRCV infection is mostly subclinical with self-limiting respiratory infection." 28.2.9: "PRCV does not cause diarrhea or villous atrophy and replicates almost exclusively in respiratory tissues. Thus, PRCV is suspected if there is antigen in lung tissues, seroconversion to TGEV/PRCV, and no signs of enteric disease." 28.2.9.1: "PRCV/TGEV differentiation is accomplished using PCR primers targeting the S gene deletion region in PRCV." 28.2.9.4: TGEV and PRCV "induce VN antibodies that are qualitatively and quantitatively similar", and "the accuracy of commercial ELISAs for differentiating US strains of PRCV and TGEV is low". shic_prcv: "Serological diagnosis of PRCV infection is frequently done using a blocking enzyme-linked immunosorbent assay (ELISA), which allows for the differentiation between PRCV and TGEV infection. This assay is available through the Iowa State University Veterinary Diagnostic Laboratory." "If enteric and respiratory disease are present concurrently, antigen detection techniques cannot differentiate PRCV and TGEV." "Nucleic acid-based identification methods are typically the most sensitive and can distinguish between PRCV and TGEV."
How this level was decided
Level 2. Level 1 is out twice over: infection is mostly subclinical so nothing prompts a test at all, and where signs do appear they are ordinary respiratory ones. The chapter's own diagnostic route is a process of exclusion -- lung antigen, seroconversion, and no enteric disease. But a validated differential RT-PCR exists that targets the S gene deletion defining the virus, and regional laboratories run it as part of the swine coronavirus multiplex. NOTE the serological limitation: neutralising antibodies to PRCV and TGEV are indistinguishable, and the US commercial ELISAs meant to separate them perform poorly, so serology alone cannot tell an owner which virus is in the herd. Level 2 confirmed, and the evidence is now specific rather than general: a differentiating blocking ELISA is named, with the laboratory that offers it. That is the level 2 shape exactly -- a validated assay, run at a diagnostic laboratory once a clinician suspects it.
C5 Production cost
Financial impact on the infected farm's cost of production
Minor: Small and generally short-lived losses with little effect on overall cost of production
CONFIRMED by Eric. The assignment reached this level from the evidence, and he has reviewed and ratified it.
Confirmed by Eric. CONFIRMED. "c5l2, agree with assessment. could even argue to make it L1 but we know in naive herds it will have a transient effect."
Basis. ch28 28.1: "PRCV induces mainly subclinical infections in pigs." 28.2.6.3: "Experimentally, PRCV infection is mostly subclinical with self-limiting respiratory infection." Clinical signs where they occur are "(1) respiratory signs (e.g. coughing, abdominal breathing, and dyspnea); (2) depression and/or anorexia; and (3) slightly decreased growth rates". Against that: "inoculation with PRRSV followed by PRCV resulted in prolonged fever with respiratory disease, reduced weight gain, and prolonged severe pneumonia", and "PRCV respiratory infection and lung lesions were exacerbated by pre-existing PRRSV infection". SECOND SOURCE, puente_2026: PRCV "rarely causes clinical signs". shic_prcv: "PRCV generally causes subclinical infection. When clinical respiratory disease is seen it is usually mild; however, severe cases have been described." "Other viral co-infections may increase the severity of respiratory disease." "PRCV is generally considered to cause mild disease and is most important for its potential to confound diagnosis of TGEV." "As PRCV infection generally causes subclinical or mild disease, to date there has been little to no effort toward prevention or control."
How this level was decided
Level 2. On its own PRCV is close to harmless -- mostly subclinical, self-limiting, and where it shows at all the cost is a cough and slightly slower growth. What lifts it off level 1 is that it does not occur on its own: PRRSV is endemic in the same herds, and the chapter records experimentally that prior PRRSV turns PRCV into prolonged severe pneumonia with reduced weight gain. Small and generally short-lived losses, with a real contribution to the respiratory disease complex. FLAGGED as a level 1 or 2 judgment. Corroborated 2026-09-04. Level 2 unchanged; Eric confirmed it on 2026-09-02 and noted he could argue L1. Level 2 confirmed. The factsheet says the industry makes little or no effort to control it, which is about as direct a statement of small, short-lived losses as a source will give.
C6 Market impact
Duration of material disruption to pork and pig markets
Negligible: Little or no material disruption to supply or demand when disease occurs on one or more farms
CONFIRMED by Eric. The assignment reached this level from the evidence, and he has reviewed and ratified it.
Confirmed by Eric. CONFIRMED. "c6l1, endemic asymptomatic agent in almost all cases, no market effect"
Basis. Section 28.2 records no trade measure, movement control or consumer response for PRCV. It has been endemic in US herds since at least 1989 and seroprevalence surveys found many asymptomatic Iowa herds positive. shic_prcv: "PRCV has been identified in Europe, the U.S., Canada, Croatia, Japan, and Korea. Current PRCV prevalence is unknown."
How this level was decided
INFERRED. Under the standing note SCORING/market_impact, a virus endemic and asymptomatic in US herds for over thirty years with no market move on record scores level 1. Level 1 confirmed -- endemic in the US for four decades with no market event.
C7 Treatment potential
Potential for treatment to improve outcomes
Little: Effective pathogen-directed treatment is available and works, or animals recover acceptably without it
Basis. ch28 28.2.6.3: "Experimentally, PRCV infection is mostly subclinical with self-limiting respiratory infection. The early antiviral effects of innate immune responses to PRCV infection, followed by cell-mediated and antibody responses, likely effectively control the infection." 28.2.5.2: "pulmonary lesions and clinical signs resolved concurrently with increased VN antibody titers." No treatment for PRCV is described anywhere in the chapter.
How this level was decided
Level 1 on the second clause, and it is stated rather than inferred: animals recover acceptably without treatment, and the chapter describes the immune mechanism by which they do it. Under the standing note SCORING/treatment_potential there is no imperative to treat, which is why the chapter never proposes one. Re-read 2026-09-04: puente_2026 describes no treatment for PRCV either, and describes the infection as rarely causing clinical signs, which is the second clause of level 1. Unchanged. Unchanged. The factsheet describes no treatment and no effort toward control, consistent with a mild, largely subclinical infection.
C8 Vaccine availability
Availability of effective vaccines or bacterins
Available, or not needed: Effective vaccines are widely available in the US or secured for national outbreak response, or the disease does not clinically or economically justify vaccinating
Basis. No PRCV vaccine is described anywhere in chapter 28. 28.1: "PRCV induces mainly subclinical infections in pigs." 28.2.10.4: "The incidence and severity of TGEV in countries with PRCV has declined since PRCV has become widespread. This suggests that prior exposure of swine to PRCV imparts partial immunity to TGEV", with sows multiply exposed to PRCV during pregnancy giving litters as little as 0-12.5% mortality on TGEV challenge. SECOND SOURCE, puente_2026, on the inversion: PRCV's spread "induced effective cross-immunity to TGEV, markedly reducing TGE incidence", leaving TGE sporadic and "primarily affecting PRCV-seronegative farms". No PRCV vaccine is mentioned in the review either. shic_prcv: "There are no PRCV vaccines that are commercially available." "A recombinant adenovirus expressing the PRCV spike glycoprotein was found to be antigenic and partially protected vaccinated piglets upon PRCV challenge." "PRCV has been investigated as a tool for vaccination against TGEV."
How this level was decided
Level 1 on the second clause -- the disease does not clinically or economically justify vaccinating against a mostly subclinical infection. NOTE THE INVERSION, which is the most interesting fact about this entry: PRCV is not a target for vaccination, it is effectively a natural vaccine. Its spread is why TGEV declined to low prevalence in Europe and the United States, and sows repeatedly exposed to it protect their litters against TGEV challenge almost completely. Vaccinating against PRCV would remove that. Corroborated 2026-09-04, and the inversion is now stated by two independent sources: PRCV is not a vaccine target, it is the reason TGE collapsed. Level 1 unchanged. Level 1 held. No commercial product, and no imperative for one given subclinical to mild disease -- the first route in the standing note. The experimental adenovirus vaccine shows the target is tractable, which matters for level 3 cells but not here, where the missing product is not a gap because the disease does not warrant one. Note the inversion worth remembering: PRCV is more interesting as a VACCINE than as a disease, having been investigated as a tool against TGEV.
Levels and evidence are generated from data/assignments/porcine_respiratory_coronavirus.yml; the overview is authored in data/overviews/porcine_respiratory_coronavirus.md. Do not hand-edit this page — corrections go in data/assignments/CORRECTIONS.yml.
Quoted material marked Basis is from Zimmerman JJ, Karriker LA, Ramirez A, Schwartz KJ, Stevenson GW, Zhang J, eds. Diseases of Swine, 12th edition. Hoboken: Wiley Blackwell, 2025 — except where another source is named in the quotation itself.